| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 44 | 2023 | 363 | 13.800 |
Why?
|
| Arthralgia | 14 | 2023 | 121 | 5.280 |
Why?
|
| Osteoarthritis, Knee | 14 | 2023 | 381 | 4.390 |
Why?
|
| Pain | 16 | 2023 | 391 | 4.080 |
Why?
|
| Arthritis, Experimental | 12 | 2020 | 125 | 3.620 |
Why?
|
| Hyperalgesia | 8 | 2023 | 46 | 3.390 |
Why?
|
| Disease Models, Animal | 25 | 2023 | 724 | 3.360 |
Why?
|
| Chronic Pain | 8 | 2023 | 112 | 3.270 |
Why?
|
| ADAM Proteins | 17 | 2019 | 64 | 3.060 |
Why?
|
| Animals | 60 | 2023 | 4552 | 2.750 |
Why?
|
| Mice | 36 | 2023 | 1607 | 2.590 |
Why?
|
| Nociceptors | 6 | 2023 | 19 | 2.350 |
Why?
|
| Ganglia, Spinal | 11 | 2023 | 57 | 2.200 |
Why?
|
| Endopeptidases | 6 | 2019 | 29 | 1.650 |
Why?
|
| Procollagen N-Endopeptidase | 9 | 2019 | 14 | 1.640 |
Why?
|
| Synovitis | 3 | 2022 | 22 | 1.590 |
Why?
|
| Nociception | 4 | 2019 | 9 | 1.550 |
Why?
|
| Knee Joint | 9 | 2021 | 797 | 1.540 |
Why?
|
| Cartilage, Articular | 23 | 2018 | 524 | 1.540 |
Why?
|
| Neurons | 3 | 2017 | 374 | 1.420 |
Why?
|
| Proprotein Convertases | 7 | 2015 | 8 | 1.410 |
Why?
|
| Aggrecans | 12 | 2019 | 146 | 1.410 |
Why?
|
| Analgesics | 3 | 2020 | 108 | 1.280 |
Why?
|
| Ehlers-Danlos Syndrome | 3 | 2023 | 7 | 1.220 |
Why?
|
| Nerve Growth Factor | 5 | 2019 | 31 | 1.210 |
Why?
|
| Serine Endopeptidases | 5 | 2015 | 17 | 1.190 |
Why?
|
| Mice, Inbred C57BL | 13 | 2023 | 432 | 1.170 |
Why?
|
| Humans | 72 | 2023 | 29337 | 1.140 |
Why?
|
| Menisci, Tibial | 6 | 2020 | 172 | 1.140 |
Why?
|
| Pain Management | 3 | 2018 | 143 | 1.130 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 20 | 1.100 |
Why?
|
| Synovial Membrane | 6 | 2022 | 81 | 1.070 |
Why?
|
| Behavior, Animal | 3 | 2017 | 105 | 1.060 |
Why?
|
| Immunity, Innate | 3 | 2020 | 90 | 1.030 |
Why?
|
| Cytokines | 10 | 2019 | 347 | 1.020 |
Why?
|
| Neuroimmunomodulation | 3 | 2020 | 9 | 0.950 |
Why?
|
| Receptors, CCR2 | 4 | 2021 | 8 | 0.950 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2019 | 358 | 0.900 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2018 | 32 | 0.880 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2023 | 33 | 0.880 |
Why?
|
| Male | 38 | 2023 | 15621 | 0.870 |
Why?
|
| Publishing | 1 | 2022 | 38 | 0.830 |
Why?
|
| Mice, Knockout | 9 | 2023 | 303 | 0.820 |
Why?
|
| Nerve Growth Factors | 2 | 2023 | 44 | 0.780 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 20 | 0.740 |
Why?
|
| Gene Expression | 4 | 2020 | 226 | 0.730 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 28 | 0.720 |
Why?
|
| Joints | 4 | 2014 | 97 | 0.710 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 80 | 0.700 |
Why?
|
| Calcium | 3 | 2018 | 491 | 0.690 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2017 | 17 | 0.680 |
Why?
|
| Rats | 6 | 2018 | 854 | 0.670 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2008 | 215 | 0.670 |
Why?
|
| ADAMTS4 Protein | 10 | 2019 | 16 | 0.660 |
Why?
|
| Protease Inhibitors | 3 | 2013 | 15 | 0.640 |
Why?
|
| Stifle | 2 | 2015 | 11 | 0.640 |
Why?
|
| Proteoglycans | 14 | 2008 | 337 | 0.630 |
Why?
|
| Clozapine | 1 | 2017 | 10 | 0.620 |
Why?
|
| Neural Inhibition | 1 | 2017 | 10 | 0.620 |
Why?
|
| Publication Bias | 1 | 2017 | 7 | 0.600 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 2 | 0.590 |
Why?
|
| Antirheumatic Agents | 3 | 2015 | 92 | 0.590 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 56 | 0.580 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 314 | 0.560 |
Why?
|
| ADAMTS5 Protein | 9 | 2018 | 27 | 0.560 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 699 | 0.550 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 27 | 0.540 |
Why?
|
| Microglia | 1 | 2016 | 124 | 0.540 |
Why?
|
| Tibial Meniscus Injuries | 2 | 2015 | 89 | 0.510 |
Why?
|
| RNA, Messenger | 4 | 2023 | 323 | 0.510 |
Why?
|
| Enzyme Activation | 3 | 2009 | 109 | 0.480 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 13 | 0.470 |
Why?
|
| Mice, Inbred DBA | 9 | 2009 | 50 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 260 | 0.460 |
Why?
|
| Disease Progression | 5 | 2020 | 787 | 0.450 |
Why?
|
| Obesity | 1 | 2016 | 291 | 0.450 |
Why?
|
| Lipopolysaccharides | 6 | 2023 | 127 | 0.440 |
Why?
|
| Signal Transduction | 3 | 2023 | 482 | 0.430 |
Why?
|
| Collagen | 8 | 2001 | 102 | 0.420 |
Why?
|
| Membrane Proteins | 2 | 2009 | 173 | 0.400 |
Why?
|
| alpha-Macroglobulins | 2 | 2015 | 12 | 0.380 |
Why?
|
| Cells, Cultured | 12 | 2015 | 676 | 0.360 |
Why?
|
| Antigens, CD | 1 | 2009 | 99 | 0.350 |
Why?
|
| Enzyme Inhibitors | 3 | 2009 | 145 | 0.340 |
Why?
|
| Female | 16 | 2023 | 16197 | 0.330 |
Why?
|
| Extracellular Matrix Proteins | 6 | 2007 | 127 | 0.330 |
Why?
|
| Amino Acid Sequence | 9 | 2010 | 193 | 0.330 |
Why?
|
| Cartilage | 2 | 2008 | 148 | 0.330 |
Why?
|
| Arthritis | 5 | 2000 | 107 | 0.330 |
Why?
|
| Interleukin-1 | 4 | 2003 | 78 | 0.330 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 78 | 0.310 |
Why?
|
| Molecular Sequence Data | 8 | 2011 | 246 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 113 | 0.310 |
Why?
|
| Interleukin-12 | 5 | 2001 | 38 | 0.310 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2017 | 26 | 0.300 |
Why?
|
| Phenotype | 4 | 2020 | 355 | 0.300 |
Why?
|
| Inflammation | 2 | 2022 | 344 | 0.300 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 2 | 2017 | 7 | 0.300 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 324 | 0.280 |
Why?
|
| Calgranulin A | 2 | 2016 | 4 | 0.280 |
Why?
|
| Disintegrins | 1 | 2005 | 1 | 0.280 |
Why?
|
| Metalloproteases | 1 | 2005 | 5 | 0.280 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 248 | 0.270 |
Why?
|
| Biomarkers | 3 | 2019 | 689 | 0.270 |
Why?
|
| Peptides | 5 | 2012 | 95 | 0.270 |
Why?
|
| Synovial Fluid | 6 | 2012 | 123 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 153 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2018 | 451 | 0.250 |
Why?
|
| Protein Conformation | 3 | 2011 | 69 | 0.240 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 24 | 0.240 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2003 | 10 | 0.240 |
Why?
|
| Caspase 1 | 1 | 2003 | 14 | 0.240 |
Why?
|
| Cattle | 9 | 2011 | 217 | 0.230 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2001 | 17 | 0.230 |
Why?
|
| Albuterol | 2 | 2001 | 15 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 391 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 49 | 0.230 |
Why?
|
| Kinetics | 6 | 2010 | 225 | 0.220 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 14 | 0.210 |
Why?
|
| Skin Abnormalities | 1 | 2021 | 2 | 0.210 |
Why?
|
| Catalysis | 2 | 2013 | 13 | 0.210 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 9 | 0.210 |
Why?
|
| Aged | 9 | 2022 | 9448 | 0.210 |
Why?
|
| Indomethacin | 1 | 2001 | 9 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1113 | 0.200 |
Why?
|
| Mutation | 2 | 2020 | 383 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 107 | 0.200 |
Why?
|
| Collagen Type V | 1 | 2020 | 3 | 0.200 |
Why?
|
| Blotting, Western | 5 | 2008 | 170 | 0.190 |
Why?
|
| Cannabis | 1 | 2000 | 6 | 0.190 |
Why?
|
| Cannabidiol | 1 | 2000 | 4 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 138 | 0.190 |
Why?
|
| Calcium Channels | 2 | 2022 | 129 | 0.190 |
Why?
|
| Matrix Metalloproteinases | 2 | 2018 | 22 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 117 | 0.190 |
Why?
|
| Microarray Analysis | 1 | 2020 | 8 | 0.190 |
Why?
|
| Alarmins | 1 | 2019 | 2 | 0.180 |
Why?
|
| Skin | 1 | 2020 | 117 | 0.180 |
Why?
|
| Health Impact Assessment | 1 | 2019 | 4 | 0.180 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1999 | 5 | 0.180 |
Why?
|
| Models, Theoretical | 1 | 2020 | 91 | 0.180 |
Why?
|
| Cost of Illness | 1 | 2019 | 54 | 0.170 |
Why?
|
| Th1 Cells | 4 | 2000 | 29 | 0.170 |
Why?
|
| Glutamic Acid | 3 | 2009 | 32 | 0.170 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2009 | 45 | 0.170 |
Why?
|
| Phylogeny | 2 | 2009 | 63 | 0.160 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 7 | 0.160 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 5 | 0.160 |
Why?
|
| Fibronectins | 2 | 2009 | 29 | 0.160 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 2 | 0.160 |
Why?
|
| Zinc | 2 | 2016 | 35 | 0.160 |
Why?
|
| Low Back Pain | 1 | 2019 | 139 | 0.160 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 7 | 0.160 |
Why?
|
| Middle Aged | 14 | 2019 | 9823 | 0.160 |
Why?
|
| Recombinant Proteins | 7 | 2010 | 251 | 0.160 |
Why?
|
| Joint Instability | 1 | 2021 | 387 | 0.150 |
Why?
|
| Protein Binding | 3 | 2008 | 127 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 788 | 0.150 |
Why?
|
| Chemokines, CC | 1 | 2017 | 8 | 0.150 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 115 | 0.150 |
Why?
|
| Receptors, Bradykinin | 1 | 2016 | 1 | 0.150 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2016 | 1 | 0.150 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2016 | 1 | 0.150 |
Why?
|
| Voltage-Gated Sodium Channels | 1 | 2016 | 1 | 0.150 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 1 | 0.150 |
Why?
|
| Acid Sensing Ion Channel Blockers | 1 | 2016 | 1 | 0.150 |
Why?
|
| Bradykinin Receptor Antagonists | 1 | 2016 | 2 | 0.150 |
Why?
|
| Acid Sensing Ion Channels | 1 | 2016 | 2 | 0.150 |
Why?
|
| Osteonecrosis | 1 | 2017 | 19 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 30 | 0.150 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 11 | 0.150 |
Why?
|
| Bibliometrics | 1 | 2017 | 24 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 2016 | 36 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 31 | 0.150 |
Why?
|
| Macrophages | 2 | 2012 | 128 | 0.150 |
Why?
|
| Models, Anatomic | 1 | 2016 | 52 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2017 | 159 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2017 | 103 | 0.140 |
Why?
|
| Random Allocation | 1 | 2016 | 146 | 0.140 |
Why?
|
| NAV1.7 Voltage-Gated Sodium Channel | 1 | 2016 | 1 | 0.140 |
Why?
|
| Chemokines, CXC | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 5 | 0.140 |
Why?
|
| Drug Design | 2 | 2013 | 30 | 0.140 |
Why?
|
| Reference Values | 1 | 2016 | 227 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2017 | 81 | 0.140 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2016 | 15 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 462 | 0.140 |
Why?
|
| Autophagy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2015 | 20 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2016 | 124 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2016 | 156 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 553 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2011 | 81 | 0.130 |
Why?
|
| Hyaluronic Acid | 5 | 2012 | 94 | 0.130 |
Why?
|
| Interferon-gamma | 4 | 2000 | 109 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1994 | 96 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2015 | 238 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 254 | 0.120 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 17 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 44 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2010 | 21 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2004 | 437 | 0.110 |
Why?
|
| Epitopes | 3 | 2015 | 81 | 0.110 |
Why?
|
| Intestines | 1 | 1994 | 107 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2012 | 8 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2012 | 10 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 27 | 0.110 |
Why?
|
| Joint Diseases | 1 | 1994 | 110 | 0.110 |
Why?
|
| Injections, Intra-Articular | 2 | 2012 | 88 | 0.110 |
Why?
|
| Catalytic Domain | 2 | 2011 | 9 | 0.110 |
Why?
|
| Spinal Diseases | 1 | 1994 | 150 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2008 | 35 | 0.100 |
Why?
|
| Amides | 1 | 2011 | 21 | 0.100 |
Why?
|
| Cell Line | 3 | 2004 | 298 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2009 | 61 | 0.100 |
Why?
|
| Chondrocytes | 2 | 2009 | 197 | 0.100 |
Why?
|
| Lymph Nodes | 3 | 2000 | 70 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 24 | 0.100 |
Why?
|
| Body Fluids | 1 | 2010 | 19 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 26 | 0.100 |
Why?
|
| Binding Sites | 3 | 2007 | 71 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2010 | 30 | 0.090 |
Why?
|
| Time Factors | 4 | 2019 | 1616 | 0.090 |
Why?
|
| Hindlimb | 2 | 2000 | 23 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 678 | 0.090 |
Why?
|
| Models, Biological | 2 | 2010 | 343 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2009 | 22 | 0.090 |
Why?
|
| Alanine | 1 | 2009 | 9 | 0.090 |
Why?
|
| Collagen Type II | 1 | 2009 | 31 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 441 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 58 | 0.090 |
Why?
|
| Point Mutation | 1 | 2009 | 30 | 0.090 |
Why?
|
| Temperature | 2 | 2007 | 76 | 0.090 |
Why?
|
| Weight-Bearing | 1 | 2009 | 164 | 0.090 |
Why?
|
| Organ Size | 1 | 2009 | 107 | 0.090 |
Why?
|
| Morphine | 1 | 2009 | 79 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2009 | 100 | 0.080 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 2 | 2007 | 4 | 0.080 |
Why?
|
| Lectins, C-Type | 5 | 2006 | 106 | 0.080 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2007 | 2 | 0.080 |
Why?
|
| Benzeneacetamides | 1 | 2007 | 11 | 0.080 |
Why?
|
| Piperidines | 1 | 2007 | 32 | 0.080 |
Why?
|
| Tibia | 1 | 2009 | 259 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 5 | 0.080 |
Why?
|
| Peptide Library | 1 | 2007 | 1 | 0.080 |
Why?
|
| Piroxicam | 3 | 1994 | 5 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 36 | 0.080 |
Why?
|
| Osmolar Concentration | 2 | 2005 | 30 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 215 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 369 | 0.070 |
Why?
|
| Femur | 1 | 2009 | 396 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2007 | 169 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2006 | 99 | 0.070 |
Why?
|
| Immunotherapy | 3 | 2001 | 62 | 0.070 |
Why?
|
| Phenylmercury Compounds | 1 | 2005 | 1 | 0.070 |
Why?
|
| Gait | 1 | 2009 | 404 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 148 | 0.070 |
Why?
|
| Risk Factors | 1 | 2012 | 2443 | 0.070 |
Why?
|
| Cell Division | 3 | 2000 | 113 | 0.060 |
Why?
|
| Adult | 7 | 2019 | 8601 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 4851 | 0.060 |
Why?
|
| Furin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Methylamines | 1 | 2004 | 4 | 0.060 |
Why?
|
| Drosophila | 1 | 2004 | 7 | 0.060 |
Why?
|
| Nasal Septum | 1 | 2004 | 9 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 1994 | 108 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 101 | 0.060 |
Why?
|
| Hypesthesia | 1 | 2023 | 8 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2023 | 80 | 0.060 |
Why?
|
| Substrate Specificity | 3 | 2007 | 26 | 0.060 |
Why?
|
| Sulfur Radioisotopes | 5 | 1994 | 13 | 0.060 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 3 | 2006 | 27 | 0.060 |
Why?
|
| Spondylitis, Ankylosing | 2 | 1994 | 44 | 0.060 |
Why?
|
| Mitochondria | 1 | 2022 | 78 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 531 | 0.050 |
Why?
|
| Sensory Receptor Cells | 1 | 2021 | 7 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 638 | 0.050 |
Why?
|
| Antibodies | 2 | 1999 | 65 | 0.050 |
Why?
|
| Ion Channels | 1 | 2023 | 189 | 0.050 |
Why?
|
| Remission Induction | 1 | 2001 | 96 | 0.050 |
Why?
|
| Zymosan | 1 | 2000 | 6 | 0.050 |
Why?
|
| Peritoneum | 1 | 2000 | 18 | 0.050 |
Why?
|
| Granulocytes | 1 | 2000 | 23 | 0.050 |
Why?
|
| Niflumic Acid | 2 | 1990 | 2 | 0.050 |
Why?
|
| Nicotinic Acids | 2 | 1990 | 3 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2000 | 140 | 0.050 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 5 | 0.050 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 8 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2000 | 125 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 209 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 1999 | 7 | 0.040 |
Why?
|
| Sepharose | 3 | 1994 | 5 | 0.040 |
Why?
|
| Mast Cells | 1 | 1999 | 26 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1999 | 118 | 0.040 |
Why?
|
| Chromatography, Affinity | 2 | 2010 | 9 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2001 | 495 | 0.040 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 213 | 0.040 |
Why?
|
| Quality of Life | 1 | 2023 | 662 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 14 | 0.040 |
Why?
|
| Transfection | 3 | 2007 | 125 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 1997 | 4 | 0.040 |
Why?
|
| Sulfur | 2 | 1994 | 5 | 0.040 |
Why?
|
| Dogs | 2 | 2010 | 253 | 0.040 |
Why?
|
| Microscopy, Electron | 2 | 1994 | 70 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 1997 | 132 | 0.040 |
Why?
|
| Rheumatoid Nodule | 2 | 1993 | 2 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 145 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1995 | 7 | 0.040 |
Why?
|
| Cricetinae | 1 | 2015 | 36 | 0.030 |
Why?
|
| Thoracic Diseases | 1 | 1995 | 1 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 70 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1995 | 10 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 1994 | 3 | 0.030 |
Why?
|
| Cell Communication | 1 | 1994 | 29 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1994 | 43 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1994 | 19 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1993 | 2 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 8 | 0.030 |
Why?
|
| Glycosaminoglycans | 2 | 2010 | 51 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 266 | 0.030 |
Why?
|
| Viscosity | 1 | 2012 | 10 | 0.030 |
Why?
|
| Hydrogels | 1 | 2012 | 9 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2012 | 11 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1992 | 29 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 86 | 0.030 |
Why?
|
| Succinates | 1 | 2011 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2011 | 8 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2011 | 28 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1992 | 61 | 0.020 |
Why?
|
| Chondroitin | 1 | 2010 | 6 | 0.020 |
Why?
|
| Versicans | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 39 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 33 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1990 | 14 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 3478 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2010 | 16 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 16 | 0.020 |
Why?
|
| Static Electricity | 1 | 2010 | 45 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 48 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 37 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2009 | 2 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| Down-Regulation | 2 | 1999 | 112 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 241 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2007 | 5 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 14 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 19 | 0.020 |
Why?
|
| Protein Folding | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2007 | 2 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2007 | 2 | 0.020 |
Why?
|
| Alkynes | 1 | 2007 | 9 | 0.020 |
Why?
|
| Benzoxazines | 1 | 2007 | 9 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2007 | 29 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2007 | 50 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2007 | 25 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2007 | 29 | 0.020 |
Why?
|
| Matrilin Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2007 | 12 | 0.020 |
Why?
|
| ADAMTS1 Protein | 1 | 2007 | 1 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 10 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2007 | 16 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 22 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 53 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 53 | 0.020 |
Why?
|
| Virus Replication | 1 | 2007 | 92 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 64 | 0.020 |
Why?
|
| HIV Infections | 1 | 1994 | 970 | 0.020 |
Why?
|
| CD4 Antigens | 2 | 1997 | 35 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 284 | 0.020 |
Why?
|
| P-Selectin | 1 | 2004 | 3 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2004 | 3 | 0.020 |
Why?
|
| Ligands | 1 | 2004 | 55 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 4 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 12 | 0.020 |
Why?
|
| RNA Interference | 1 | 2004 | 33 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2004 | 35 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 85 | 0.010 |
Why?
|
| HIV-1 | 1 | 2007 | 438 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 264 | 0.010 |
Why?
|
| Clone Cells | 2 | 1993 | 20 | 0.010 |
Why?
|
| Thymidine | 2 | 1993 | 7 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1993 | 11 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 1993 | 146 | 0.010 |
Why?
|
| Carbon Radioisotopes | 2 | 1990 | 7 | 0.010 |
Why?
|
| Forecasting | 1 | 2000 | 117 | 0.010 |
Why?
|
| Culture Techniques | 2 | 1989 | 26 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 129 | 0.010 |
Why?
|
| Rolipram | 1 | 1997 | 2 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 35 | 0.010 |
Why?
|
| Transferrin | 1 | 1995 | 6 | 0.010 |
Why?
|
| Somatomedins | 1 | 1995 | 4 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 56 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 44 | 0.010 |
Why?
|
| Insulin | 1 | 1995 | 92 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 123 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1995 | 119 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1995 | 642 | 0.010 |
Why?
|
| Glycosides | 1 | 1993 | 2 | 0.010 |
Why?
|
| Leucine | 1 | 1993 | 15 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1993 | 66 | 0.010 |
Why?
|
| Adolescent | 2 | 1990 | 2279 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1993 | 4 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 198 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1993 | 110 | 0.010 |
Why?
|
| Femur Head | 1 | 1993 | 66 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 211 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1992 | 5 | 0.010 |
Why?
|
| Ileum | 1 | 1992 | 22 | 0.010 |
Why?
|
| Tritium | 1 | 1991 | 14 | 0.010 |
Why?
|
| Mitosis | 1 | 1991 | 9 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1991 | 30 | 0.010 |
Why?
|
| Gels | 1 | 1990 | 9 | 0.010 |
Why?
|
| Sodium Radioisotopes | 1 | 1990 | 1 | 0.010 |
Why?
|
| Chromatography, Agarose | 1 | 1990 | 2 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 220 | 0.010 |
Why?
|
| Culture Media | 1 | 1989 | 38 | 0.010 |
Why?
|